MaxCyte MXCT Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Assay And Other Service Revenue | $2.05M+4.3% | $1.97M— | —— | —— | —— | |
| License | $13.22M+6.9% | $12.37M-0.8% | $12.47M-2.5% | $12.8M-16.5% | $15.33M-6.6% | |
| Revenue by Geography | ||||||
| Non Us | $12.63M+5.7% | $11.95M+0.3% | $11.92M-0.2% | $11.94M+0.4% | $11.89M-7.5% | |
| US | $19.66M-6.7% | $21.08M-6.3% | $22.5M-5.5% | $23.81M-7.7% | $25.79M+0.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does MaxCyte break its business down?
- MaxCyte (MXCT) reports revenue by product across 2 parts — Assay And Other Service Revenue and License. Each is extracted from the segment footnotes and tracked over time.
- Where does MaxCyte's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in MaxCyte's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
